Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00135811 · ClinicalTrials.gov registry record · Phase 3
Focal Segmental Glomerulosclerosis Clinical Trial (FSGS-CT)
A Phase 3 study, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- Completed
- Registry status
- Phase 3
- Development phase
- 207
- Enrollment target
NCT00135811 is a Phase 3 study that has completed, run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The registered enrollment target is 207 participants.
The verdict
NCT00135811, a Phase 3 study, has completed, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 207 participants
- Enrollment target
Study Summary
The FSGS Clinical Trial is a multi-center, prospective, controlled, open label randomized trial designed to determine if treatment with mycophenolate mofetil (MMF) in conjunction with pulse steroids is superior to treatment with Cyclosporine-A (CSA) in inducing remission from proteinuria over 12 months.
Interventions
- DRUG Cyclosporin
- DRUG MMF and Dexamethasone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 207 participants |
| Start Date | 2004-11 |
| Est. Completion | 2009-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00135811
The ClinicalTrials.gov registry entry for NCT00135811 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 207 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cyclosporin is the first listed.
NCT00135811 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00135811 about?
NCT00135811 is a clinical study titled "Focal Segmental Glomerulosclerosis Clinical Trial (FSGS-CT)". The FSGS Clinical Trial is a multi-center, prospective, controlled, open label randomized trial designed to determine if treatment with mycophenolate mofetil (MMF) in conjunction with pulse steroids is superior to treatment with Cyclosporine-A (CSA) in inducing remission from proteinuria over 12 mon...
What is the current status of trial NCT00135811?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 207 participants. The study started on 2004-11. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00135811?
The interventions under investigation include: Cyclosporin (DRUG), MMF and Dexamethasone (DRUG).
Who is sponsoring clinical trial NCT00135811?
This trial is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.